Drug-resistant tuberculosis: collaborative regional leadership required

Suman S Majumdar, Ben J Marais, Justin T Denholm and Warwick J Britton
Med J Aust 2014; 200 (5): . || doi: 10.5694/mja13.00239
Published online: 17 March 2014

The drug-resistant tuberculosis crisis provides urgency and focus for coordinated action to improve regional health and development

  • 1 Centre for International Health, Burnet Institute, Melbourne, VIC.
  • 2 Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney, Sydney, NSW.
  • 3 Discipline of Paediatrics and Child Health, University of Sydney, The Children's Hospital at Westmead, Sydney, NSW.
  • 4 Victorian Infectious Diseases Service, Royal Melbourne Hospital, Peter Doherty Institute, Melbourne, VIC.
  • 5 Department of Microbiology and Immunology, University of Melbourne, Melbourne, VIC.
  • 6 National Health and Medical Research Council Centre of Research Excellence in Tuberculosis Control, Centenary Institute and University of Sydney, Sydney, NSW.


The opinions expressed are our own. They have, however, arisen and been refined from discussions within the newly formed Australasian Tuberculosis Forum, a coalition of organisations and individuals working in TB research, care and prevention. A full list of supporting organisations can be found at

Competing interests:

No relevant disclosures.

  • 1. Abubakar I, Zignol M, Falzon D, et al. Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis 2013; 13: 529-539.
  • 2. World Health Organization. Global tuberculosis report 2013. Geneva: WHO, 2013. (accessed Nov 2013).
  • 3. Department of Foreign Affairs and Trade. East Asia leaders agree to collective action on malaria. Canberra: Australian Government, 2012. (accessed Nov 2013).
  • 4. World Health Assembly. Prevention and control of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis (WHA 62.15). Geneva: World Health Organization, 2009. (accessed Sep 2013).
  • 5. Cohen T, Murray M. Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nat Med 2004; 10: 1117-1121.
  • 6. Marais BJ, Mlambo CK, Rastogi N, et al. Epidemic spread of multidrug-resistant tuberculosis in Johannesburg, South Africa. J Clin Microbiol 2013; 51: 1818-1825.
  • 7. International Civil Society Support. Cost of inaction: a report on how inadequate investment in the Global Fund to Fight AIDS, Tuberculosis and Malaria will affect millions of lives. Amsterdam: ICSS, 2013. (accessed Sep 2013).
  • 8. Lumb R, Bastian I, Carter R, et al. Tuberculosis in Australia: bacteriologically confirmed cases and drug resistance, 2010. A report of the Australian Mycobacterium Reference Laboratory Network. Commun Dis Intell Q Rep 2013; 37: E40-E46.
  • 9. Fitzpatrick C, Floyd K. A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis. Pharmacoeconomics 2012; 30: 63-80.
  • 10. Wu J, Dalal K. Tuberculosis in Asia and the Pacific: the role of socioeconomic status and health system development. Int J Prev Med 2012; 3: 8-16.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.